


Introducing government use of patents on essential medicines in Thailand, 2006 - 2007

Policy analysis with key lessons learned and recommendations









Sripen Tantivess Nusaraporn Kessomboon Chotiros Laongbua

International Health Policy Program, Thailand
June 2008

Table of contents

Pre	ice 11	.1
Ac	nowledgements i	V
Αb	ract \	7
	e of contentsv	
	of tables and figures	
Lis	of abbreviationsxi	iii
1.	ntroduction 1	1
2.	ackground information: International framework on medicine	
	atents and the Thai experience	5
	2.1 TRIPS agreement and public health	5
	2.2 TRIPS flexibilities and the Doha Declaration on TRIPS and	
	Public Health	8
	2.3 Experiences of developing countries on the use of	
	compulsory licensing for medicines 1	.1
	2.4 Past effort to ensure access to medicines in Thailand	.6
	2.5 Price negotiations prior to the government use of medicine	
	patents in 2006-7 2	23
3.	Agenda setting and adoption of the Thai policy on government	
	ise of medicine patents2	26
	3.1 How the use of TRIPS flexibilities attracted policymakers	
	3.2 On what grounds the government use policy was adopted?	32
	3.3 The motives behind the introduction of government use	
	provision	35
4.	How the government use of medicine patents was put into	
	pperation	41
	4.1 The MOPH's White Paper'	12
	4.2 The establishment of new government mechanisms	44

	4.3 Networking with local and international partners	49		
	4.4 Importation and distribution of medicines under the			
	government use programme	52		
	4.5 Seeking support on the use of TRIPS flexibilities from the WHO	54		
5.	Interplay between local stakeholders	58		
6.	The roles of international organisations	7 1		
7.	Pressing movements of drug companies, their representatives and			
	country governments	78		
	7.1 Motives of the opposition to the government use policy	78		
	7.2 Reactions of some industrialized nations	81		
	7.3 Pressing movements of the trans-national drug industry	95		
8.	Non-governmental organisations as key players	113		
9.	Immediate benefits of the enforcement of government use			
	measure	119		
	9.1 Beneficial implications for Thailand's health systems	119		
	9.2 Spill-over effects of the Thai action	125		
10. The way forward				
	10.1 Anticancer: medicines in the government use pipeline			
	10.2 Government's plan on local drug production			
	10.3 Looking beyond the 2007 general election: will the			
	government use policy continue?	131		
11. Discussion, lessons learned and policy recommendations				
	11.1 Agenda setting and policy adoption			
	11.2 Policy formulation and implementation	136		

11.3	Policy networks: exchanges of resources and their	
	contributions	139
11.4	Looking at the Thai CL policy through the lens of power	142
11.5	Why Thailand's government use initiative generated	
	serious tensions: the matters of interests and awareness of	
	potential policy transfer	144
11.6	Lessons drawn on the government use of medicine patents in	
e ⁱ	Thailand	147
11. <i>7</i>	Policy recommendations	149
D. C.		
Keterence	S	151